Cybin logo

CybinNYSE American: CYBN

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Canada

IPO:

13 September 2019

Next earnings report:

14 February 2025

Last dividends:

N/A

Next dividends:

N/A
$227.92 M
-74%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-89%vs. 3y high
44%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Wed, 20 Nov 2024 00:51:44 GMT
$11.40+$0.05(+0.44%)

Dividend

No data over the past 3 years
No data over the past 3 years

Analysts recommendations

Institutional Ownership

CYBN Latest News

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
businesswire.com13 November 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program evaluating the efficacy and safety of CYB003 for the adjunctive treatment of Major Depressive Disorder (“MDD”). The program name, PARADIGM, represents the.

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
businesswire.com24 October 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 12,122,741 (‘741) with claims to the composition of matter of lead preclinical candidates in the Company's CYB005 phene.

Cybin: Top Value Psychedelic Stock
seekingalpha.com15 October 2024 Sentiment: POSITIVE

Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and provider convenience. Cybin's trial results, robust IP portfolio, and solid financials de-risk its path to FDA approval, with a market cap significantly lower than competitors.

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
businesswire.com03 October 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer, will participate in the Water Tower Research Fireside Chat Series taking place on Tuesday, October 8, 2024, at 3:00 p.m. ET. The fireside chat will be ho.

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”
globenewswire.com27 September 2024 Sentiment: POSITIVE

Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”. Water Tower Research has published an Initiation of Coverage Report on Cybin, Inc. (NYSE AM: CYBN) titled, “A Leader in Novel Neuropsychiatry Therapeutics”.

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
businesswire.com24 September 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Amir Inamdar, Cybin's Chief Medical Officer, will participate in a panel discussion at the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit taking place virtually on September 26, 2024. T.

Cybin Provides Corporate Update on Upcoming Clinical Milestones
businesswire.com19 September 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today reported recent clinical accomplishments and key upcoming clinical milestones. “We are making rapid advancements in our two lead clinical programs – CYB003, our proprietary deuterated psilocin program in development for the.

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale
seekingalpha.com19 September 2024 Sentiment: POSITIVE

Cybin's CYB003 and CYB004 programs show promising results in treating depression and anxiety, with CYB003 achieving 75% remission in Phase 2 trials. Phase 3 trials, leveraging a strong IP portfolio and a streamlined operational structure.

Cybin Announces Completion of Previously Announced Share Consolidation
businesswire.com19 September 2024 Sentiment: POSITIVE

TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American: CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that it has filed articles of amendment to consolidate the Company's issued and outstanding common shares (the “Common Shares”) on the basis of one new Common Share for every 38 existing Common Shares (the.

3 Biotech Stocks That Could Make Your Summer Unforgettable
investorplace.com30 July 2024 Sentiment: POSITIVE

If you want to do well with biotech stocks, trade the anticipation of news. Look at Structure Therapeutics (NASDAQ: GPCR ), for example.

  • 1(current)

What type of business is Cybin?

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.

What sector is Cybin in?

Cybin is in the Healthcare sector

What industry is Cybin in?

Cybin is in the Biotechnology industry

What country is Cybin from?

Cybin is headquartered in Canada

When did Cybin go public?

Cybin initial public offering (IPO) was on 13 September 2019

What is Cybin website?

https://www.cybin.com

Is Cybin in the S&P 500?

No, Cybin is not included in the S&P 500 index

Is Cybin in the NASDAQ 100?

No, Cybin is not included in the NASDAQ 100 index

Is Cybin in the Dow Jones?

No, Cybin is not included in the Dow Jones index

When was Cybin the previous earnings report?

No data

When does Cybin earnings report?

The next expected earnings date for Cybin is 14 February 2025